Cranoc Lipid Study in Renal Transplantation

NCT ID: NCT00223041

Last Updated: 2011-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiovascular disease after renal transplantation is an important problem. Patients after renal transplantation with low LDL-Levels (\<130mg/dl) receive Fluvastatin 80mg/day (or no medication, to look for the cardiovascular outcome with and without statins.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiovascular disease after renal transplantation is an important problem. Patients after renal transplantation with low LDL-Levels (\<130mg/dl) receive Fluvastatin 80mg/day (or no medication, to look for the cardiovascular outcome with and without statins.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A (therapy with fluvastatin 80mg retard)

kidney transplants receive in addition fluvastatin 80mg retard for 3 years

Group Type NO_INTERVENTION

No interventions assigned to this group

B

no therapy with fluvastatin

Group Type PLACEBO_COMPARATOR

Fluvastatin

Intervention Type DRUG

Arm A receives fluvastatin Arm b receives no fluvastatin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluvastatin

Arm A receives fluvastatin Arm b receives no fluvastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients (18 - 65, inclusive)
* cadaver and living kidney transplantation (1. Ntx, 2. Ntx)
* LDL-cholesterol ≤ 130mg/dl (-3 Mo until start of Tx)
* Patients with a history of Myocard infarct: LDL-Cholesterol ≤ 110mg/dl
* Immunsuppression: Tacrolimus in combination with steroids or Mycophenolat Mofetil
* patients indulgence

Exclusion Criteria

* statin before the study

* LDL-Cholesterol \>130mg/dl before transplantation
* Instabil Angina, Myocard infarct \<6 months before transplantation
* symptomatic Hypothyreosis
* child bearing, lactating
* elavated liver encymes (\> 2x elavated: AST, ALT, bilirubine, PCK)
* Fibrates are not allowed
* multiorgantransplantation
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Schleswig-Holstein

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Kiel, department of Nephrology

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lutz Renders, MD

Role: PRINCIPAL_INVESTIGATOR

University of Scghleswig-Holstein, Campus Kiel, Department of Nephrology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Schleswig-Holstein, Campus Kiel, Department of Nephrology

Kiel, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.